ARTICLE | Company News

Vifor, ChemoCentryx expand kidney partnership

December 23, 2016 12:22 AM UTC

ChemoCentryx Inc. (NASDAQ:CCXI) and the Vifor Pharma Ltd. subsidiary of Galenica Ltd. (SIX:GALN) said they will expand their kidney disease partnership to include ChemoCentryx candidate CCX140, an inhibitor of CC chemokine receptor 2 (CCR2; CD192). The partners already share rights to avacopan (CCX168), a small molecule complement receptor 5a (C5aR; CD88) inhibitor, under a May 2016 deal.

Under the new deal, Vifor will receive rights outside the U.S. and China to CCX140 to treat rare renal disease, while ChemoCentryx will retain U.S. and China rights. Vifor may opt to obtain worldwide rights to CCX140 for more prevalent forms of chronic kidney disease (CKD), in which case ChemoCentryx would have the option to co-commercialize the candidate in the U.S. In 2014, CCX140 met the primary endpoint of a Phase II trial to treat diabetic nephropathy (see BioCentury Extra, Dec. 12, 2014)...

BCIQ Company Profiles

ChemoCentryx Inc.